Denmark backs generic lung drug in threat to GSK sales

December 18, 2013 6:15 PM

5 0

Denmark backs generic lung drug in threat to GSK sales

LONDON (Reuters) - Denmark has approved the sale of an inhaled lung drug that analysts think is a generic copy of GlaxoSmithKline's $8 billion-a-year blockbuster Advair, threatening its future sales.

UK firm Vectura said on Wednesday that its partner Sandoz - the generics division of Novartis - had received approval for AirFluSal Forspiro, which was previously known as VR315.

Read more

To category page

Loading...